Company intelligence / Profile preview
Nanjing Calmhome Cell & Gene Engineering Institute
Nanjing, Jiangsu Sheng, China
- Ownership
- Private
- Development stage
- Other
01
Overview
Multiple clinical trials underway (5 identified by May 2025), including Phase 1 trials for CAR-T products targeting hematological malignancies and mesothelin-positive pancreatic cancer. No commercialization or Phase 2/3 assets yet; all clinical results are early-stage and focused on safety and early efficacy endpoints.
- Therapeutic areas
- OncologyInfectious DiseasesHematologyOtherNeurologyEndocrinology
- Modalities
- CAR-T cell therapyUniversal CAR-T cell therapyFusion proteinMonoclonal antibody
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Tianjin Medical University Cancer Institute and Hospital
Beyond the preview
Go deeper on Nanjing Calmhome Cell & Gene Engineering Institute.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Nanjing Calmhome Cell & Gene Engineering Institute.